Health & Medicinearticle2026-10-27

Presentation at EASD 2026 Symposium: Metabolic benefits of glucagon receptor/GLP-1 receptor dual agonism beyond weight reduction: Additional insights from the SYNCHRONIZE®-1 phase 3 clinical trial

Open access1 citations

Abstract

The above is a presentation part of the "Glucagon receptor/GLP-1 receptor dual agonism in people with obesity and type 2 diabetes: insights from the SYNCHRONIZE Phase 3 studies of survodutide" Symposium at EASD 2026.

// Source

View paper (DOI)Open access versionOpenAlexBoehringer IngelheimPublished 2026-10-27

Authors: Kirsi Hannele Pietiläinen